Skip to content
Use caution Drug recall · FDA · Published August 10, 2022

Nephron Recalls Ketorolac Injection Due to Cross-Contamination Risk

Nephron Sc Inc recalls specific lots of Ketorolac Tromethamine Injection due to cGMP deviations that may lead to potential cross-contamination.

🇺🇸 FDA recall #D-1354-2022DrugNephron ›
Take action

Contact the company

Recalling firmNephron Sc Inc4500 12th Street Ext · West Columbia, SC 29172-3025
✎ GovInfoNow plain-language explainer

Nephron Sc Inc is recalling Ketorolac Tromethamine Injection, USP 60 mg/2 mL packaged in 2 mL single dose vials. The recall addresses current Good Manufacturing Practice (cGMP) deviations that could result in potential cross-contamination of the drug product. This specific batch has an expiration date of August 31, 2022. Read more at govinfonow.com/recall/34371-nephron-recalls-ketorolac-injection-due-to-cross-contamination-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/34371-nephron-recalls-ketorolac-injection-due-to-cross-contamination-risk · Updated October 10, 2026 · FDA enforcement record: FDA #D-1354-2022

Cite this page

“Nephron Recalls Ketorolac Injection Due to Cross-Contamination Risk.” GovInfoNow, updated October 10, 2026. https://govinfonow.com/recall/34371-nephron-recalls-ketorolac-injection-due-to-cross-contamination-risk. Based on FDA recall #D-1354-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1354-2022%22&limit=1).

The FDA announced on August 10, 2022, that Nephron Sc Inc voluntarily recalled Ketorolac Tromethamine Injection due to cGMP deviations leading to potential cross-contamination. The recall affects 5,040 vials distributed nationwide.

How to tell if you have it

  • Brand: Nephron
  • Product: Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL)
  • Packaging: 2 mL single dose vials
  • NDC: 0487-6232-01
  • Lot #: 023011
  • Expiration: 8/31/2022

The hazard

The recall was issued because of cGMP deviations that could lead to potential cross-contamination. The FDA classified the recall as Class II.

Context

GovInfoNow's records show Nephron Sc Inc has had three other recalls since January 12, 2023, including a February 23, 2023, sterile water recall for potential product carryover and a January 13, 2023, racepinephrine inhaler recall for short fill. Other recent recalls of similar products include Wells Pharma's April 1, 2026, fentanyl citrate injectable solution recall for cGMP deviations and Baxter's August 6, 2026, vasopressin injection recall for CGMP deviations risk.

How to tell if you have this one

Check if you have Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL) in 2 mL single dose vials. Look for NDC 0487-6232-01 and Lot number 023011 with an expiration date of 8/31/2022.

  • Brand
    Nephron
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Inventory

    Verify if you possess the recalled vials by checking the NDC, lot number, and expiration date against the recall details.

  2. Contact Healthcare Provider

    If you have received this medication, consult your healthcare provider regarding the potential risk of cross-contamination.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.1 years after the firm started it.

1. Firm started the recall: Aug 10, 202212. FDA classified it Class II: Aug 17, 202223. Published in FDA’s Enforcement Report: Aug 24, 202234. FDA terminated the recall: Sep 24, 2024420222024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1354-2022 (August 10, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1354-2022 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 10, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA